» Articles » PMID: 32573351

Ethnomedicines of Indian Origin for Combating COVID-19 Infection by Hampering the Viral Replication: Using Structure-based Drug Discovery Approach

Overview
Date 2020 Jun 24
PMID 32573351
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

In the present study, we have explored the interaction of the active components from 10 different medicinal plants of Indian origin that are commonly used for treating cold and respiratory-related disorders, through molecular docking analysis. In the current scenario, COVID-19 patients experience severe respiratory syndromes, hence it is envisaged from our study that these traditional medicines are very likely to provide a favourable effect on COVID-19 infections. The active ingredients identified from these natural products are previously reported for antiviral activities against large group of viruses. Totally 47 bioactives identified from the medicinal plants were investigated against the structural targets of SARS-CoV-2 (Mpro and spike protein) and human ACE2 receptor. The top leads were identified based on interaction energies, number of hydrogen bond and other parameters that explain their potency to inhibit SARS-CoV-2. The bioactive ligands such as Cucurbitacin E, Orientin, Bis-andrographolide, Cucurbitacin B, Isocucurbitacin B, Vitexin, Berberine, Bryonolic acid, Piperine and Magnoflorine targeted the hotspot residues of SARS-CoV-2 main protease. In fact, this protease enzyme has an essential role in mediating the viral replication and therefore compounds targeting this key enzyme are expected to block the viral replication and transcription. The top scoring conformations identified through docking analysis were further demonstrated with molecular dynamics simulation. Besides, the stability of the conformation was studied in detail by investigating the binding free energy using MM-PBSA method. Overall, the study emphasized that the proposed hit Cucurbitacin E and orientin could serve as a promising scaffold for developing anti-COVID-19 drug.Communicated by Ramaswamy H. Sarma.

Citing Articles

SARS-CoV-2 drug resistance and therapeutic approaches.

Batool S, Chokkakula S, Jeong J, Baek Y, Song M Heliyon. 2025; 11(2):e41980.

PMID: 39897928 PMC: 11786845. DOI: 10.1016/j.heliyon.2025.e41980.


In-silico and in-vitro studies to identify potential inhibitors of SARS-CoV-2 spike protein from Omani medicinal plants.

Al-Mahrami N, Nair S, Al Mawali A, Beema Shafreen R, Ullah S, Ahsan Halim S Heliyon. 2024; 10(21):e39649.

PMID: 39553680 PMC: 11564015. DOI: 10.1016/j.heliyon.2024.e39649.


Synergistic Effect of Nilavembu Choornam-Gold Nanoparticles on Antibiotic-Resistant Bacterial Susceptibility and Contact Lens Contamination-Associated Infectious Pathogenicity.

Almutleb E, Ramachandran S, Khan A, El-Hiti G, Alanazi S Int J Mol Sci. 2024; 25(4).

PMID: 38396792 PMC: 10889799. DOI: 10.3390/ijms25042115.


Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets.

He Z, Yuan J, Zhang Y, Li R, Mo M, Wang Y Pharm Biol. 2023; 61(1):1186-1210.

PMID: 37605622 PMC: 10446791. DOI: 10.1080/13880209.2023.2241518.


Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies.

Toigo L, Dos Santos Teodoro E, Guidi A, Gancedo N, Petruco M, Melo E Daru. 2023; 31(1):51-68.

PMID: 37195402 PMC: 10191091. DOI: 10.1007/s40199-023-00461-3.